SG healthtech startup Mesh Bio bags $3.5m in Series A funding

Mesh Bio, a Singapore-based health deep tech startup, has announced raising $3.5 million in its Series A funding round anchored by Southeast Asia-focused venture capital investor East Ventures.

The round was joined by Elev8, SEEDS Capital and other existing shareholders. The funding comes three months after the startup secured regulatory approval for one of its digital twin technologies in Singapore.

In October, it received approval from Singapore’s Health Sciences Authority (HSA) to market its HealthVector Diabetes as a Software Medical Device (SaMD).

With the fresh funding, the company said it will offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines.

“We are excited to announce the closure of our Series A funding, this pivotal step empowers us to expand our digital health solutions for chronic disease management in Southeast Asia,” said Dr. Andrew Wu, co-founder and CEO of Mesh Bio.

Mesh Bio was founded in 2018 by Wu and Arsen Batagov to deliver digital solutions to address challenges in patient management and rising chronic diseases in the region.

Chronic diseases such as cardiovascular diseases and diabetes impose a major and growing burden on health and development in the SE Asia region, where 62% of all deaths are due to non-communicable diseases, World Health Organisation data shows.